- Home
- LVLU vs COCP Comparison
LVLU vs COCP Comparison
Compare LVLU & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LVLU | COCP |
|---|---|---|
| Founded | 1996 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5M | 14.1M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | LVLU | COCP |
|---|---|---|
| Price | $5.45 | $1.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $15.00 | $6.00 |
| AVG Volume (30 Days) | ★ 246.3K | 62.8K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $285,413,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.53 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.98 | $0.90 |
| 52 Week High | $18.60 | $3.26 |
Technical Indicators
Market Signals| Indicator | LVLU | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 55.23 | 51.97 |
| Support Level | $5.02 | $1.01 |
| Resistance Level | $5.64 | $1.08 |
| Average True Range (ATR) | 0.42 | 0.05 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 61.11 | 89.24 |
Price Performance
Historical ComparisonAbout LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).